Merus | Executive Management

Lex Bakker (CDO)

Lex Bakker holds a Ph.D in Tumor Immunology from the University of Nijmegen and was a postdoctoral fellow at the DNAX Research Institute (Palo Alto, CA). Prior to joining Merus, Lex worked at biotechnology company Crucell where he directed the preclinical and clinical development of a human antibody combination for rabies post-exposure prohylaxis.

Shelley Margetson (CFO)

Prior to joining Merus, Shelley Margetson was VP Finance of PanGenetics B.V. PanGenetics is a therapeutic antibody development company that specialises in taking antibodies from the late research stage through to clinical proof of concept. Shelley has worked in the biotechnology industry since 2001 for companies located in the UK, France and Netherlands. Shelley is an Associate of the Chartered Institute of Management Accountants.

Ton Logtenberg (CEO)

Ton Logtenberg holds a Ph.D in Medical Biology and is the founder of Merus BV. Ton was a professor at the department of Immunology in Utrecht, The Netherlands and a co-founder of biotechnology company Crucell NV serving the company as executive vice-president and Chief Scientific Officer. Ton is an expert in the field of antibody engineering with more than 80 scientific publications and 20 patents to his name.

John de Kruif (CSO)

John de Kruif holds a Ph.D in Biology spending his scientific career on phage display and engineering of human antibodies. Before joining Merus, John was Director Antibody research and Development at biotechnology company Crucell and, among others, responsible for the development of a cocktail of 2 anti-rabies mAbs, currently in phase II of clinical testing.

Mark Throsby (COO)

Mark Throsby holds a Ph.D in Immunology. Before joining Merus, he was the Director Antibody Discovery at Dutch biotechnology company Crucell were he was responsible for successful initiation of projects in viral and bacterial diseases leading to successful clinical development programs and licensing deals.